Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: Possible role in diabetic nephropathy

被引:84
作者
McLennan, SV [1 ]
Fisher, E
Martell, SY
Death, AK
Williams, PF
Lyons, JG
Yue, DK
机构
[1] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[2] Royal Prince Alfred Hosp, Dept Endocrinol, Sydney, NSW, Australia
[3] Royal Prince Alfred Hosp, Kanematsu Inst, Sydney, NSW, Australia
关键词
matrix metalloproteinase; plasmin; transforming growth; factor-beta; diabetic nephropathy; matrix degradation;
D O I
10.1046/j.1523-1755.2000.07713.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Diabetic nephropathy is characterized by an accumulation of mesangium matrix that correlates well with the loss of kidney function. High glucose concentration is known to increase the synthesis of many matrix components. Recently, we have shown that degradation of matrix also decreases in diabetes. The major enzymes responsible for matrix degradation are the matrix metalloproteinases. The physiology of these enzymes is complex and their activity is tightly regulated at many levels. At the transcriptional level matrix metalloproteinase (MMP) expression is increased by protein kinase C (PKC) agonists, and some growth factors. In contrast transforming growth factor (TGF)-beta call decrease MMP expression. Once synthesized, MMPs are secreted as inactive pro-enzymes that are activated by other MMPs or plasmin. To effect this, plasmin must be liberated from plasminogen in the pericellular environment. In turn, activated MMPs can be inhibited by binding to specific inhibitors known as tissue inhibitor of metalloproteinases (TIMP). Cell culture and animal studies have shown that high glucose (HG) decreases expression of MMFs and increases expression of TIMPs. HG can also affect MMP activation by decreasing plasmin availability and reducing expression of a membrane-bound MMP called MT1-MMP. How HG induces these changes remains to be fully elucidated. One possibility is that HG can increase TGF-beta, which may in turn alter MMP promoter activity; this area is currently being studied in our laboratory.
引用
收藏
页码:S81 / S87
页数:7
相关论文
共 84 条
[1]  
Abboud H E, 1997, Kidney Int Suppl, V60, pS3
[2]   Cellular activation of mesangial gelatinase A by cytochalasin D is accompanied by enhanced mRNA expression of both gelatinase A and its membrane-associated gelatinase A activator (MT-MMP) [J].
Ailenberg, M ;
Silverman, M .
BIOCHEMICAL JOURNAL, 1996, 313 :879-884
[3]   THE AP-1 SEQUENCE IS NECESSARY BUT NOT SUFFICIENT FOR PHORBOL INDUCTION OF COLLAGENASE IN FIBROBLASTS [J].
AUBLE, DT ;
BRINCKERHOFF, CE .
BIOCHEMISTRY, 1991, 30 (18) :4629-4635
[4]   TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[5]   INCREASED EXTRACELLULAR-MATRIX SYNTHESIS AND MESSENGER-RNA IN MESANGIAL CELLS GROWN IN HIGH-GLUCOSE MEDIUM [J].
AYO, SH ;
RADNIK, RA ;
GLASS, WF ;
GARONI, JA ;
RAMPT, ER ;
APPLING, DR ;
KREISBERG, JI .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (02) :F185-F191
[6]   PROTEOLYTIC-ENZYMES AS MEDIATORS OF GLOMERULAR INJURY [J].
BARICOS, WH ;
SHAH, SV .
KIDNEY INTERNATIONAL, 1991, 40 (02) :161-173
[7]   The AP-1 site and MMP gene regulation: What is all the fuss about? [J].
Benbow, U ;
Brinckerhoff, CE .
MATRIX BIOLOGY, 1997, 15 (8-9) :519-526
[8]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[9]  
BORDER WA, 1994, NEW ENGL J MED, V331, P1286
[10]   TGF-beta in kidney fibrosis: A target for gene therapy [J].
Border, WA ;
Noble, NA .
KIDNEY INTERNATIONAL, 1997, 51 (05) :1388-1396